Evidence map›Paper›PMID 39021640›Full record

ArticleCase reports in endocrinology2024

A Case of Myxedema Coma and Adrenal Insufficiency Post Pembrolizumab.

Andrew El Alam, Mohamad Fleifel, Dana El Masri, Bertha Maria Nassani, Jessica Abou Chaaya, Mahamadou Minkailou, Mariana Barbat, Arnaud Monier

Abstract readCase Reports
In one paragraph

Article in Case reports in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andrew El AlamEndocrinology and Metabolism Division Lebanese American University Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0009-0008-1182-6656
Mohamad FleifelEndocrinology and Metabolism Division American University of Beirut Medical Center, Beirut, Lebanon.ORCID https://orcid.org/0000-0001-8050-3393
Dana El MasriEndocrinology and Metabolism Division Lebanese American University Medical Center, Beirut, Lebanon.
Bertha Maria NassaniInternal Medicine and Clinical Immunology Division Hôtel Dieu de France Medical Center, Beirut, Lebanon.
Jessica Abou ChaayaEndocrinology and Metabolism Division American University of Beirut Medical Center, Beirut, Lebanon.
Mahamadou MinkailouEndocrinology Division Louis Pasteur Hospital, Le Coudray, France.
Mariana BarbatEndocrinology Division Louis Pasteur Hospital, Le Coudray, France.
Arnaud MonierEndocrinology Division Louis Pasteur Hospital, Le Coudray, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite their important clinical benefits, immune checkpoint inhibitors (ICIs) are associated with a spectrum of side effects known as immune-related adverse events (irAEs). These can be of various organ system backgrounds, including dermatologic, pulmonary, gastrointestinal, and endocrine. Polyglandular endocrinopathies (PLEs) post-ICIs therapy has been reported in the literature; however, to our knowledge, only a few have been documented with pembrolizumab. Conclusion: It is of high significance to explore the mechanism of action of ICIs and their side effects. PLEs can house some endocrinologic emergencies that are life threatening.

Identifiers

PMID39021640
PMCPMC11254456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.